Argenx Analyst Ratings
Oppenheimer Upgrades Argenx SE to Outperform From Perform, $546 Price Target
Gilead Sciences (GILD) Receives a Buy From TD Cowen
Oppenheimer Upgrades Argenx SE(ARGX.US) to Buy Rating, Announces Target Price $546
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Gilead Sciences Analyst Ratings
Argenx Price Target Maintained With a $519.00/Share by Wedbush
Halozyme Therapeutics Analyst Ratings
Argenx Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Wedbush Sticks to Its Buy Rating for Argenx Se (ARGX)
Truist Financial Reaffirms Their Buy Rating on Argenx Se (ARGX)
Truist Securities Adjusts Price Target on Argenx to $540 From $480, Maintains Buy Rating
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Genmab Analyst Ratings
TD Cowen Keeps Their Hold Rating on Genmab (GMAB)
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)